SCR-1481B1 | Gasdermin D inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 1 mg | $30.00 | ||
| 5 mg | $90.00 |
SCR-1481B1 (1174161-86-4) is an inhibitor of HGFR (Met) and VEGFR kinases.1 SCR-1481B1 potently suppresses gasdermin D-mediated pyroptosis via targeting of the oligomerization interface I.2 Active in vivo in a mouse model of sepsis. SCR-1481B1 acts synergistically with another gasdermin D inhibitor, Cefcapene pivoxil (Cat #10-3972), and a PD-L1 antibody to significantly enhance the antitumor activity of anti-PD-L1 therapy.
References/CItations:
- Borzilleri and Cai (2012), 4-Pyridone compounds and their use for cancer; US8258118B2
- Hu et al. (2024), Identification of two repurposed drugs targeting GSDMD oligomerization interface I to block pyroptosis; Cell Chem. Biol. 31 P2024
C24H18ClF2N4O7P·2C4H11NO3
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SCR-1481B1 (1174161-86-4) is an inhibitor of HGFR (Met) and VEGFR kinases.1 SCR-1481B1 potently suppresses gasdermin D-mediated pyroptosis via targeting of the oligomerization interface I.2 Active in vivo in a mouse model of sepsis. SCR-1481B1 acts synergistically with another gasdermin D inhibitor, Cefcapene pivoxil (Cat #10-3972), and a PD-L1 antibody to significantly enhance the antitumor activity of anti-PD-L1 therapy.
References/CItations:
- Borzilleri and Cai (2012), 4-Pyridone compounds and their use for cancer; US8258118B2
- Hu et al. (2024), Identification of two repurposed drugs targeting GSDMD oligomerization interface I to block pyroptosis; Cell Chem. Biol. 31 P2024
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
